Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Expert Sheds Light on Rare Complement-Mediated Hematologic Disorders

May 18th 2017

Ronald S. Go, MD, provides perspective on thrombotic microangiopathy and paroxysmal nocturnal hemoglobinuria, including how community physicians can properly diagnose and treat them.

Emerging BTK Inhibitor Tested in B-Cell Malignancies

May 18th 2017

BGB-3111, a second-generation BTK inhibitor, is being tested in patients with refractory B-cell lymphoid malignancies in an effort to determine whether the novel oral small molecule is a viable therapeutic option and to better understand its pharmacologic properties.

CLL-IPI an Essential Tool for Determining Treatment Approaches

May 17th 2017

Sameer A. Parikh, MD, discusses how the International Prognostic Index has assisted physicians with their patients who have CLL, the optimal sequencing of therapies, and other emerging molecular targets in this disease.

Dr. Begna on Recent Advancements in MPNs

May 16th 2017

Kebede H. Begna, MD, assistant professor of Medicine, Mayo Clinic, discusses some of the recent advancements in the field of myeloproliferative neoplasms (MPNs).

Ongoing AML Trials of Novel Agents Could Shift Field

May 15th 2017

Aref Al-Kali, MD, discusses some of the recent advancements, exciting ongoing trials, and largest unanswered questions in AML.

Subcutaneous Rituximab Results Published as FDA Decision Nears

May 15th 2017

Results from the phase III SABRINA trial showed that subcutaneous administration of rituximab produced nearly identical response rates and toxicity as IV administration in the first-line treatment of follicular lymphoma.

Ritchie Reflects on Research Underway in Myeloproliferative Neoplasms

May 10th 2017

Ellen K. Ritchie, MD, highlights current and emerging novel treatments, and the possibility of using immunotherapy to treat patients with systemic mastocytosis, advanced symptomatic hypereosinoophic disorder, myelofibrosis, and chronic myelomonocytic leukemia

Leonard Highlights Agents, Approaches in Pipeline for Hematologic Malignancies

May 10th 2017

John P. Leonard, MD, discusses advancements across hematologic malignancies and pivotal trial data he is anticipating at the 2017 ASCO Annual Meeting.

Dr. Rutherford on Double-Hit and Double-Expressor Lymphomas

May 10th 2017

Sarah Rutherford, MD, John P. Leonard, M.D./Gwirtzman Family Research Scholar in Lymphoma , assistant professor of medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the classification and prevalence of double-hit and double-expressor lymphomas.

Midostaurin Approval Brings New Hope in AML

May 10th 2017

Gail J. Roboz, MD, discusses the recent FDA approval of midostaurin and what else is emerging in the treatment landscape in AML.

Dr. Roth on Treating AYA Patients With Hodgkin Lymphoma

May 10th 2017

Lisa Giulino Roth, MD, assistant professor of Pediatrics in Medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treating adolescent and young adult patients with Hodgkin lymphoma.

Kite Reports Cerebral Edema Death in ZUMA-1 CAR T-Cell Trial

May 9th 2017

The first cerebral edema death in the ZUMA-1 CAR T-cell therapy trial was disclosed today by Kite Pharma on a conference call with investors announcing the company’s first quarter financial results.

Dr. Jain Discusses Treatment of Richter's Transformation in CLL

May 8th 2017

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with chronic lymphocytic leukemia who have developed Richter’s transformation.

Juno Hopes to Cut Production of CAR T Cells to Just 2 Days

May 8th 2017

JUNO Therapeutics announced that it hopes to accelerate its process for developing CAR T cells from weeks to just 2 days.

Neelapu Hopeful FDA Will Approve Axicabtagene Ciloleucel for NHL

May 8th 2017

Sattva S. Neelapu, MD, discusses the ZUMA-1 trial and the potential impact of these results on patients with non-Hodgkin lymphoma.

Expert Looks to Genetic Testing for Next Leap in MCL

May 8th 2017

Grzegorz S. Nowakowski, MD, discusses ongoing efforts to determine prognostic factors of mantle cell lymphoma and what other challenges lie ahead.

Dr. Leonard on Emergence of CAR T-cell Therapy in Hematologic Cancers

May 5th 2017

John P. Leonard, MD, associate dean of Clinical Research, interim chair of the Department of Medicine, Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the emergence and potential of chimeric antigen receptor (CAR) T-cell therapy across hematologic malignancies.

EU Approves Pembrolizumab for Hodgkin Lymphoma

May 5th 2017

The European Commission has approved pembrolizumab for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have progressed following autologous stem cell transplant and brentuximab vedotin, or who are transplant-ineligible and have failed brentuximab vedotin.

Lead Researcher Discusses Midostaurin in AML

May 5th 2017

Richard M. Stone, MD, discusses the impact that midostaurin could have for patients with AML, as well as ongoing research with the agent.

Freireich's Fight: Making Progress Against All Odds

May 4th 2017

Emil J. Freireich, MD, DSc, was the originator of combination chemotherapy, the primary architect of the first cure for a systemic cancer, a major contributor to the cures for half a dozen other systemic cancers and, quite possibly, the man who did the most to transform MD Anderson from a minor facility to one of the world’s leading cancer centers.